All News
Renal biopsies, while painful, remain the gold standard for diagnosing and classifying lupus nephritis. But what if there are less-invasive methods? In this article, I highlight key abstracts exploring innovative approaches.
https://t.co/ZInKmVS2Gn
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Upadacitinib in Behcet's disease - would be very much welcomed, and this open label 8 patient pilot from China is encouraging.
We saw similar data for tofacitinib before @ARD_BMJ: https://t.co/YlAQVXpnTY
JAKi (?generic) could be a fantastic option!
#ACR24 ABST2515 @RheumNow https://t.co/65friNLUOK
Links:
David Liew drdavidliew ( View Tweet)
Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA.
-Pts with nail involvement treated with IXE or ADA had higher SJC and TJC improvement vs those without involvement at W12, W24 and W52.
-IXE achieved rapid response for DAPSA-LDA as… https://t.co/SR36qCthQo https://t.co/hI3tD5hATJ
Links:
Adela Castro AdelaCastro222 ( View Tweet)
My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse
Richard Conway RichardPAConway ( View Tweet)
We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition?
Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt
NO difference in relapse rate at 26, 52 wks despite addition of Anakinra
@RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO.
There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies.
Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato
Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH
Encouraging data for JAKs in this disease; need proper trials
#ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip
Links:
Mike Putman EBRheum ( View Tweet)
Wu et al. MDA5-DM. Propensity-score cohort study. 672 patients. Tofacitinib vs CNI. Primary outcome 1 year death or lung transplant. HR 0.70 favouring tofacitinib. @RheumNow #ACR24 Abstr#1736 https://t.co/A0aHhp1q9c https://t.co/LbutJDBllr
Links:
Richard Conway RichardPAConway ( View Tweet)
Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec
Links:
Richard Conway RichardPAConway ( View Tweet)
📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved
substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52.
-PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52.
Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT
Links:
Richard Conway RichardPAConway ( View Tweet)
A picture is worth a thousand words—and so are the four abstracts behind it! At #ACR24, I highlight the benefits and risks of apremilast in #PsA.
@RheumNow
https://t.co/ospR0qEIsd
Akhil Sood MD AkhilSoodMD ( View Tweet)
de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX
Richard Conway RichardPAConway ( View Tweet)
Subgroup data from SELECT GCA, overall reinforces overall message
I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case
Take home: encouraging data, no subgroup issues
#ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3
Links:
Mike Putman EBRheum ( View Tweet)
Which subsets of GCA pt might benefit most from upadacitinib?
Sub-analysis from SELECT-GCA presented today:
💥Both relapsing and refractory disease
💥Pt w hx of PMR
💥Non-smokers
💥No hx ischemic eye dz
In general, most subgroups still favor UPA
@RheumNow #ACR24 Abst 1695 https://t.co/pX5hcX4TmR
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF+MTX>CYC/AZA. But I'm not sure what to do with these results. How does it compare to toc or ada? @RheumNow #ACR24 Abstr#1696 https://t.co/Jr6S2c6AKs https://t.co/L8pMFJ5hnj
Links:
Richard Conway RichardPAConway ( View Tweet)
Very neat simulated model of GC regimens in AAV pt on fixed RTX by @zach_wallace_md and co
Over 5 years:
- No difference in relapse btwn standard GC vs. minimal GC + avacopan
- Higher DMII rates in standard group
Adds to trial + real world data
@RheumNow #ACR24 Abst 1598
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE
Belimumab ~ 600% increase!!
@RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF
Bella Mehta bella_mehta ( View Tweet)
#SLE treatments #ACR24:
Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL))
Both improved disease activity with no difference in efficacy
Belimumab had lower infection rates
@RheumNow abst1544
Bella Mehta bella_mehta ( View Tweet)
